Coya Therapeutics (COYA) Financials

Coya Therapeutics’ latest statements show a development-stage biotechnology company with a strong cash position and minimal debt, but continued operating losses and substantial dependence on equity financing. The company’s financial profile remains highly focused on research and development rather than commercial profitability.

• Cash reserves remain substantial. Cash and equivalents were $43.2 million at June 30, 2026. Although this was down from $50.7 million at the end of the first quarter, it was well above the $29.8 million reported at June 30, 2025 and the $10.9 million reported at September 30, 2023.
• The balance sheet has limited leverage. Coya reported no long-term debt, while total liabilities were only $4.0 million compared with $43.3 million of equity. This reduces interest-rate and refinancing risk relative to companies carrying significant debt.
• Liquidity is strong in the near term. Total current assets of $47.1 million exceeded total current liabilities of $3.5 million by a wide margin, indicating considerable short-term balance-sheet flexibility.
• Revenue is higher than in the year-ago quarter. Second-quarter 2026 revenue was $243,745, up approximately 49% from $163,616 in the second quarter of 2025. All reported revenue translated into gross profit because the company recorded no cost of revenue.
• Operating expenses declined sequentially. Total operating expenses fell to $7.3 million in Q2 2026 from $7.9 million in Q1 2026, primarily because selling, general and administrative expenses declined from $3.8 million to $2.3 million.
• Research spending remains the primary use of capital. Research and development expense increased to $5.0 million in Q2 2026 from $4.1 million in Q1. This spending may support pipeline development, but it also means Coya must continue funding operations before achieving meaningful commercial scale.
• Cash burn has increased in the latest quarter. Net cash used in operating activities was $7.4 million in Q2 2026, compared with $6.2 million in Q1 and $5.8 million in Q2 2025. At the latest quarterly burn rate, the reported cash balance represents roughly six quarters of operating funding, although actual runway will depend on future spending and financing.
• Coya remains deeply unprofitable. The company posted a Q2 2026 net loss of $6.6 million, or $0.28 per diluted share. Net losses have persisted across the reported quarters, including losses of $7.2 million in Q1 2026 and $5.7 million in Q4 2025.
• Revenue remains inconsistent and insufficient to cover expenses. Quarterly revenue has ranged from $163,616 to $4.0 million across the recent periods, while operating expenses have generally remained between approximately $5.6 million and $10.0 million. Q2 2026 operating expenses were nearly 30 times revenue.
• Shareholder dilution is a continuing risk. Weighted-average basic shares increased from approximately 14.5 million in Q1 2024 to 23.5 million in Q2 2026. Coya raised approximately $11.0 million through common equity issuance in Q1 2026 and $20.3 million in Q4 2025, highlighting its reliance on issuing stock to support operations.

Overall, Coya’s improved cash balance, low liabilities and lack of debt provide a financial cushion for continued clinical development. However, the company has not yet demonstrated recurring revenue or a path to profitability, and the latest increase in cash burn reinforces the possibility of additional equity raises and dilution if operating losses continue.